Katrina Moore

PhD Student

Katrina has just completed her PhD funded by an Alzheimer’s Society studentship investigating the presymptomatic period of genetic FTD. She has a BSc in Psychology from Anglia Ruskin University and first joined the team after graduation in 2014. She was the first study co-ordinator in the GENFI study and led a large international study to bring together information about ages at onset and disease duration in genetic FTD. This work formed the first part of her PhD and was awarded the 2017 FTD UK Early Career Researcher Clinical Science Prize and the 2017 UCL Graduate Poster Competition First Prize. Further PhD work included the development of cognitive composites for clinical trials in FTD and a new app for cognitive testing called Ignite.

  • AAIC 2019 (Los Angeles, July 2019): Ignite: A novel cognitive assessment app for testing presymptomatic FTD
  • 11th ICFTD (Sydney, November 2018): GENFI-Cog: Developing a cognitive composite score for presymptomatic genetic FTD therapeutic trials
  • FTD UK 7th Annual Meeting (London, September 2017): Symptom onset in genetic FTD
  • 10th ICFTD (Munich, August 2016): Symptom onset in genetic FTD
  • A modified Camel and Cactus Test detects presymptomatic semantic impairment in genetic frontotemporal dementia within the GENFI cohort. Moore KM, Convery R, Bocchetta M, Neason M, Cash DM, Greaves CV, Russell LL, Clarke MTM, Peakman G, van Swieten J, Jiskoot L, Moreno F, Barandiaran M, Sanchez-Valle R, Borroni B, Laforce Jr R, Doré M-C, Masellis M, Tartaglia MC, Graff C, Galimberti D, Rowe JB, Finger E, Synofzik M, Karnath H-O, Vandenberghe R, de Mendonça A, Maruta C, Tagliavini F, Santana I, Ducharme S, Butler C, Gerhard A, Levin J, Danek A, Otto M, Warren JD, Rohrer JD, GENFI. Appl Neuropsychol Adult. 2020:1-8.
  • Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Moore KM, Nicholas J, Grossman M, McMillan CT, Irwin DJ, Massimo L, Van Deerlin VM, Warren JD, Fox NC, Rossor MN, Mead S, Bocchetta M, Boeve BF, Knopman DS, Graff-Radford NR, Forsberg LK, Rademakers R, Wszolek ZK,van Swieten JC, Jiskoot LC, Meeter LH, Dopper EGP, Papma JM, Snowden JS, Saxon J, Jones M, Pickering Brown S, Le Ber I, Camuzat A, Brice A, Caroppo P, Ghidoni R, Pievani M, Benussi L, Binetti G, Dickerson BC, Lucente D, Krivensky S, Graff C, Öijerstedt L, Fallström M, Thonberg H, Ghoshal N, J Morris JC, Borroni B, Benussi A, Padovani A, Galimberti D, Scarpini E, Fumagalli GG, Mackenzie IR, Hsiung GR, Sengdy P, Boxer AL, Rosen H, Taylor JB, Synofzik M, Wilke C, Sulzer P, Hodges JR, Halliday G, Kwok J, Sanchez-Valle R, Lladó A, Borrego-Ecija S, Santana I, Almeida MR, Tábuas-Pereira M, Moreno F, Barandiaran M, Indakoetxea B, Levin J, Danek A, Rowe JB, Cope TE, Otto M, Anderl-Straub S, de Mendonça A, Maruta C, Masellis M, Black SE, Couratier P, Lautrette G, Huey ED, Sorbi S, Nacmias B, Laforce Jr R, Tremblay ML, Vandenberghe R, Van Damme P, Rogalski EJ, Weintraub S, Gerhard A, Onyike CU, Ducharme S, Papageorgiou SG, Ng ASL, Brodtmann A, Finger E, Guerreiro R, Bras J, FTD Prevention Initiative, Rohrer JD. Lancet Neurol. 2020;19(2):145-156.